Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Grant K. Hunter"'
Autor:
Grant K. Hunter, Chandana A. Reddy, Eric A. Klein, Patrick Kupelian, Kenneth Angermeier, James Ulchaker, Nabil Chehade, Andrew Altman, Jay P. Ciezki
Publikováno v:
Prostate Cancer, Vol 2012 (2012)
Objective.To examine gastrointestinal (GI) and genitourinary (GU) toxicity profiles of patients treated in 1999 with external beam radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods. TThe records of 525
Externí odkaz:
https://doaj.org/article/dbbc4453394b4281b4418460facd3444
Autor:
Deborah T. Blumenthal, Robin Buerki, Mitchell Machtay, Valerie Panet-Raymond, Stephanie L. Pugh, Nirav Patil, Eashwar Somasundaram, James R. Connor, Andrew E. Sloan, H. Ian Robins, Grant K. Hunter, Marta Penas-Prado, Justin D. Lathia, Serah Choi, Kristin A Waite, John C. Flickinger, Lynn S. Ashby, Maria Werner-Wasik, Joshua B. Rubin, Michael E. Berens, Merideth M Wendland, Mark R. Gilbert, Jill S. Barnholtz-Sloan, Minesh P. Mehta
Publikováno v:
Journal of Neuro-Oncology
Background/purpose Glioblastoma (GBM) is the most common primary malignant brain tumor. Sex has been shown to be an important prognostic factor for GBM. The purpose of this study was to develop and independently validate sex-specific nomograms for es
Autor:
Michael E, Scheurer, Renke, Zhou, Mark R, Gilbert, Melissa L, Bondy, Erik P, Sulman, Ying, Yuan, Yanhong, Liu, Elizabeth, Vera, Merideth M, Wendland, Emad F, Youssef, Volker W, Stieber, Ritsuko R, Komaki, John C, Flickinger, Lawrence C, Kenyon, H Ian, Robins, Grant K, Hunter, Ian R, Crocker, Samuel T, Chao, Stephanie L, Pugh, Terri S, Armstrong
Publikováno v:
Neuro-oncology advances. 4(1)
We sought to identify clinical and genetic predictors of temozolomide-related myelotoxicity among patients receiving therapy for glioblastoma.Patients (23% of patients developed myelotoxicity (Myelotoxicity during concurrent chemoradiation with temoz
Autor:
Michael E Scheurer, Renke Zhou, Mark R Gilbert, Melissa L Bondy, Erik P Sulman, Ying Yuan, Yanhong Liu, Elizabeth Vera, Merideth M Wendland, Emad F Youssef, Volker W Stieber, Ritsuko R Komaki, John C Flickinger, Lawrence C Kenyon, H Ian Robins, Grant K Hunter, Ian R Crocker, Samuel T Chao, Stephanie L Pugh, Terri S Armstrong
Publikováno v:
Neuro-Oncology Advances. 4
Background We sought to identify clinical and genetic predictors of temozolomide-related myelotoxicity among patients receiving therapy for glioblastoma. Methods Patients (n = 591) receiving therapy on NRG Oncology/RTOG 0825 were included in the anal
Autor:
Grant K. Hunter, Mark R. Gilbert, H. Ian Robins, David Brachman, Ian R. Crocker, Jeffrey S. Wefel, Stephanie L. Pugh, Terri S. Armstrong, Merideth M Wendland, Kevin S. Roof, Minhee Won, Paul D. Brown, Minesh P. Mehta
Publikováno v:
Neuro Oncol
Background Results of NRG Oncology RTOG 0825 reported adding bevacizumab to standard chemoradiation did not significantly improve survival endpoints and resulted in greater decline in neurocognitive function (NCF) and patient-reported outcomes (PRO)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9919ba2d2e50c394c7a9df213e46a97d
https://europepmc.org/articles/PMC8661434/
https://europepmc.org/articles/PMC8661434/
Autor:
W.A. Yung, Susan M. Chang, Aline Paixão Becker, I Robins, Erica Hlavin Bell, Jean-Paul Bahary, Arnab Chakravarti, Helen A. Shih, Brian D. Kavanagh, Jessica Fleming, Lynn S. Ashby, Stephanie L. Pugh, Grant K. Hunter, Christopher J. Schultz, Cynthia Timmers, Maria Werner-Wasik, Joseph P. McElroy
Publikováno v:
International journal of radiation oncology, biology, physics. 108(5)
Autor:
Ziyan Liu, Minhee Won, Edward G. Shaw, Andrea L. Salavaggione, David G. Johnson, Aline Paixão Becker, Ian R. Crocker, Minesh P. Mehta, Jessica Fleming, Arnab Chakravarti, Erica Hlavin Bell, Kenneth Aldape, Cynthia Timmers, Peixin Zhang, Dennis E. Bullard, Albert Murtha, Geoffrey R. Barger, Christopher J. Schultz, David Brachman, Grant K. Hunter, Mark R. Gilbert, Nadia Laack, Stanley Z. Gertler, Keith J. Stelzer, Jan C. Buckner, Joseph P. McElroy, Paul D. Brown
Publikováno v:
J Clin Oncol
PURPOSE NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375 ) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b12ab71274bee194a6b2919dfa8f74
https://europepmc.org/articles/PMC7527157/
https://europepmc.org/articles/PMC7527157/
Autor:
Frank S. Lieberman, Deborah T. Blumenthal, Luis Souhami, Minesh P. Mehta, Dennis C. Shrieve, Benjamin W. Corn, Kirsten Hopkins, Egils Valeinis, Felix Bokstein, David G Brachman, Peixin Zhang, Maria Werner-Wasik, Minhee Won, Grant K. Hunter, Merideth M Wendland, Mark R. Gilbert, Steven P. Howard, Cliff G. Robinson, Paul D. Brown
Publikováno v:
Neuro-Oncology. 20:966-974
Background We previously reported the unexpected finding of significantly improved survival for newly diagnosed glioblastoma in patients when radiation therapy (RT) was initiated later (>4 wk post-op) compared with earlier (≤2 wk post-op). In that
Autor:
Aline Paixão Becker, Nadia N. Laack, Stanley Z. Gertler, Minhee Won, David B. Johnson, Jessica Fleming, Arnab Chakravarti, Joseph P. McElroy, Erica Hlavin Bell, Ian R. Crocker, D. Brachman, Minesh P. Mehta, Christopher J. Schultz, Albert Murtha, Grant K. Hunter, Edward G. Shaw
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 105:S78-S79
Autor:
Erica Hlavin Bell, Grant K. Hunter, Susan M. Chang, Helen A. Shih, Kenneth D. Aldape, Jean Paul Bahary, H. Ian Robins, Karl Belanger, Paul D. Brown, Minesh P. Mehta, Maria Werner-Wasik, Geoffrey R. Barger, Mark R. Gilbert, David Brachman, Kurt A. Jaeckle, Peixin Zhang, Christopher J. Schultz, Carol A. Dolinskas, Marta Penas-Prado, Arnab Chakravarti, J. Gregory Cairncross, David Schiff
Publikováno v:
Neuro-oncology, vol 19, iss 2
Background The primary objective of this study was to compare the overall survival (OS) of patients with anaplastic astrocytoma (AA) treated with radiotherapy (RT) and either temozolomide (TMZ) or a nitrosourea (NU). Secondary endpoints were time to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::691642fd38a32e75a654975ddb89b9e6
https://escholarship.org/uc/item/3zw2g691
https://escholarship.org/uc/item/3zw2g691